Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Mikael J. Pittet, Ph.D.

Co-Author

This page shows the publications co-authored by Mikael Pittet and Christopher Garris.
Connection Strength

4.055
  1. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-? and IL-12. Immunity. 2018 12 18; 49(6):1148-1161.e7.
    View in: PubMed
    Score: 0.819
  2. ER Stress in Dendritic Cells Promotes Cancer. Cell. 2015 Jun 18; 161(7):1492-3.
    View in: PubMed
    Score: 0.644
  3. Therapeutically reeducating macrophages to treat GBM. Nat Med. 2013 Oct; 19(10):1207-8.
    View in: PubMed
    Score: 0.572
  4. Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy. Sci Immunol. 2021 Jul 02; 6(61).
    View in: PubMed
    Score: 0.245
  5. LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects. Cell Stress. 2019 Oct 14; 3(11):348-360.
    View in: PubMed
    Score: 0.217
  6. Recording the wild lives of immune cells. Sci Immunol. 2018 09 07; 3(27).
    View in: PubMed
    Score: 0.201
  7. Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhigh neutrophils. Science. 2017 12 01; 358(6367).
    View in: PubMed
    Score: 0.191
  8. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med. 2017 05 10; 9(389).
    View in: PubMed
    Score: 0.184
  9. PF4 Promotes Platelet Production and Lung Cancer Growth. Cell Rep. 2016 11 08; 17(7):1764-1772.
    View in: PubMed
    Score: 0.177
  10. SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science. 2016 Apr 08; 352(6282):242-6.
    View in: PubMed
    Score: 0.169
  11. Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity. 2016 Feb 16; 44(2):343-54.
    View in: PubMed
    Score: 0.168
  12. Common TLR5 mutations control cancer progression. Cancer Cell. 2015 Jan 12; 27(1):1-3.
    View in: PubMed
    Score: 0.156
  13. Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. Clin Cancer Res. 2020 06 15; 26(12):2827-2837.
    View in: PubMed
    Score: 0.056
  14. Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy. Theranostics. 2019; 9(26):8426-8436.
    View in: PubMed
    Score: 0.055
  15. Tissue-Specific Macrophage Responses to Remote Injury Impact the Outcome of Subsequent Local Immune Challenge. Immunity. 2019 11 19; 51(5):899-914.e7.
    View in: PubMed
    Score: 0.055
  16. Arg1 expression defines immunosuppressive subsets of tumor-associated macrophages. Theranostics. 2018; 8(21):5842-5854.
    View in: PubMed
    Score: 0.051
  17. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat Biomed Eng. 2018 08; 2(8):578-588.
    View in: PubMed
    Score: 0.049
  18. Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging. Nat Commun. 2017 02 08; 8:14293.
    View in: PubMed
    Score: 0.045
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.